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Triple mutations in three major genes for long QT syndrome are very
rare and cause complicated phenotypes with ventricular arrhythmia
S. Ohno1, J. Wu1, Y. Mizusawa1, K. Sonoda1, H. Itoh1, T. Makiyama2,
M. Horie1. 1Shiga University of Medical Science, Department of Cardiovascular
and Respiratory Medicine, Otsu, Japan; 2Kyoto University Graduate School of
Medicine, Department of Cardiovascular Medicine, Kyoto, Japan
Background: Long QT syndrome (LQTS) is characterized by QT prolongation
in 12-lead ECG and peculiar ventricular tachycardia called as torsade de pointe
(TdP). The disease frequency is estimated around 1 per 2000. The main cause
of LQTS is mutations in genes encoding cardiac ion channels and more than
60% of patients carried mutations in KCNQ1, KCNH2 and SCN5A. These gene
mutations cause LQT1, LQT2 and LQT3. The frequency of compound or double
mutations has been reported as 4 to 10%, however, patients with triple mutations
have been rarely reported.
Objective: The aim of this study is to search for the frequency of triple mutation
carriers in LQTS and clarify the detailed clinical severity of them.
Methods and results: The cohort of this study consisted of 1015 LQTS
probands and their family members. We performed genetic screening for genes
related with LQTS including KCNQ1, KCNH2, and SCN5A by Sanger methods or
targeted resequencing using next generation sequencer. We identified two unre-
lated probands with three mutations in three genes (0.2%). The first proband was
a 9 year-old boy who experienced syncope while playing, and KCNQ1-R174C,
KCNH2-E1039X, and SCN5A-E428K were identified. Another proband was an
11 year-old boy who suffered cardiac arrest while playing ball game. He carried
KCNQ1-T587M, KCNH2-R148W, and SCN5A-K1244N. The minor allele frequen-
cies of all mutations were less than 0.001 in ethnic matched healthy controls. We
further performed clinical and genetic analysis of family members for three gen-
erations in both families (figure). Only probands were the three mutation carriers
except for 2 years-old sister. Several members with one or two mutations showed
QT prolongation, however, their symptoms were mild or none. These data sug-
gest that the accumulation of the pathogenic mutations caused severe pheno-
type.
Family trees
Conclusion: Although the frequency of triple mutation carriers was very rare
(0.2%) among patients who diagnosed with LQTS, screening for three genes and
identification of mutations would be indispensable for the clinical treatment and
familial analysis.
P3472 | BEDSIDE
Evaluation of the diagnostic process of arrhythmogenic cardiogenetic
disease: how to improve the yield?
C.A. Houck, J.M.E. Van Der Does, A. Heida, D.E. Burghouwt, V. Van Gastel,
J.A.E. Kammeraad, J.M.A. Verhagen, A.J.Q.M. Muskens, N.M.S. De Groot.
Erasmus Medical Center, Cardiology, Rotterdam, Netherlands
Background: Over the past years, knowledge on the genetic aetiology of car-
diac arrhythmias has increased enormously. A combination of both genetic and
cardiac evaluation is important in the diagnostic approach of patients at risk for
inherited cardiac arrhythmias (ICA). In order to obtain an acceptable diagnostic
yield, a structured protocol for evaluation of patients at risk is needed.
Purpose: The goal of this study is 1) to evaluate the diagnostic process of ICA
in various patient groups at risk and 2) to propose a protocol for cardiogenetic
evaluation of these patients.
Methods: In this retrospective study we included 825 patients >18 years who vis-
ited the outpatient clinic for cardiogenetic evaluation. Patients were categorized
by the reason of their visit: an out of hospital cardiac arrest (OHCA, N=69), unex-
plained ventricular tachycardia (VT, N=62), symptoms suspected for ICA (N=208),
family screening with (N=253) or without (N=190) a known diagnosis in the index
patient and carriers of a cardiogenetic mutation or variant of unknown significance
(N=43) after referral from the clinical genetics department. Outcomes of ECG,
24h-Holter recording, echocardiogram, exercise ECG, drugtest, signal-averaged
ECG, MRI, biopsy and genetic testing were analysed.
Results: A cardiogenetic disease was found in 250 patients (30%), including
Brugada syndrome (N=112), arrhythmogenic right ventricular cardiomyopathy
(ARVC, N=36), possible/borderline ARVC (N=35), long QT syndrome (N=39), fa-
milial idiopathic ventricular fibrillation (N=18), catecholaminergic polymorphic VT
(N=8), short QT syndrome (N=1) and sick sinus syndrome (N=1). Twenty patients
were diagnosed with a cardiac disease other than the aforementioned arrhythmo-
genic cardiogenetic diagnoses, mainly including cardiomyopathies. A mutation or
unclassified variant without phenotypic manifestations was found in an additional
3% of patients. In OHCA and VT patients, the cause of the arrhythmia remained
unknown in 64% and 52%, respectively. The lowest yield was obtained in patients
who came for family screening without a known diagnosis in the index patient
(16%). Holter recordings were most often abnormal in LQTS patients, showing a
prolonged QT interval in 51%. An MRI was abnormal in >75% of patients with
possible/borderline/definite ARVC or other cardiac diagnoses. A mutation or vari-
ant of unknown significance was found in 95% of genetically tested patients with
LQTS, in contrast to 28% of patients with Brugada syndrome.
Conclusion: After cardiogenetic evaluation of patients at risk for ICA, a cardiac
diagnosis or a mutation or unclassified variant without a phenotype could be es-
tablished in 35%. Based on the outcomes of evaluation in all patients at risk, a
structured protocol was proposed to increase the yield of cardiogenetic evaluation
and to avoid unnecessary (non-)invasive diagnostic testing.
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Clinical characteristics and prognosis of patients with non-type 1
Brugada-pattern electrocardiogram and a history of ventricular
fibrillation
T. Kamakura, M. Wada, K. Ishibashi, Y. Inoue, K. Miyamoto, S. Nagase, T. Noda,
T. Aiba, S. Yasuda, H. Ogawa, S. Kamakura, K. Kusano. National Cerebral and
Cardiovascular Center, Department of Cardiovascular Medicine, Suita, Japan
Introduction: The clinical characteristics and prognosis of patients with non-type
1 (saddleback type) Brugada-pattern electrocardiogram (BrP-ECG) in the right
precordial leads (V1-V3) and a history of ventricular fibrillation (VF) have not been
fully investigated.
Methods: We investigated clinical characteristics and prognosis of consecutive
15 patients (12 males, mean age at the first VF: 38.6±12.1 years) with a history
of VF and non-type 1 BrP-ECG, which never changed to type 1 BrP-ECG in the
standard or high costal ECG recordings (2nd and 3rd) even after drug test by a
sodium channel blocker, and compared them with those of 36 patients with type 1
Brugada syndrome (BrS) and documented VF. Both the standard and high-costal
ECGs were recorded at each follow-up visit, and none of the ECGs of patients
with non-type 1 BrP-ECG revealed type 1 BrP-ECG.
Results: During a mean follow up of 111±60 months, the recurrence rate of VF
was similar between patients with non-type 1 BrP-ECG and BrS (8/15: 53% vs.
17/36: 47%, p=0.77). Analysis of the onset of VF showed a high incidence of
nocturnal VF episodes (non-type 1: 73%, BrS: 53%) and VF with sudden on-
set pattern (non-type 1: 67%, BrS: 88%) with relatively long-coupled premature
ventricular contractions similar to those of BrS (non-type 1: 388.8±50.6 ms, BrS:
388.2±59.8 ms). Among 15 patients with non-type 1 BrP-ECG and VF episodes,
13 (87%) showed inferolateral early repolarization (ER) at baseline, and all pa-
tients with VF recurrence had inferolateral ER.
Conclusion: Patients with non-type 1 BrP-ECG, which never changed to type 1
ECG, and a history of VF showed similar clinical characteristics and prognosis to
those of type 1 BrS patients. Inferolateral ER was identified in most patients with
non-type 1 BrP-ECG and VF.
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Prognostic significance of disrhythmias in patients with familiar
amyloid polyneuropathy
A.R. Gaspar Lopes Francisco, N. Cortez-Dias, M.N. Menezes, T. Guimaraes,
G. Lima Da Silva, R. Placido, A. Magalhaes, C. Inacio, F.J. Pinto, C. Azevedo
Coutinho. Cardiology Department, Santa Maria University Hospital, CHLN,
CAML, CCUL, Faculty of Medicine, UL, Lisboa, Portugal
Background: Rhythm disturbances and conduction defects are common conse-
quences of cardiac amyloid infiltration in familial amyloid polyneuropathy (FAP)
V30M-TTR. The occurrence of dysrhythmias appears to increase with the sever-
ity of the disease but its prognostic value is still unknown.
Purpose: To evaluate the occurrence of arrhythmias according to the patient’s
age and the duration of symptoms and to analyze its prognostic value.
Methods: Prospective observational study of consecutive patients with FAP
V30M-TTR who underwent annual cardiac evaluation including Holter recording.
Results: During a median follow-up of 55 months, 223 patients were evaluated
(44±14 years; 54.3% female) and a total of 777 Holter recordings were performed.
It was found that with increasing age, the number of premature supraventricular
(Pearson R=0.246, P<0.001, Spearman’s Rho=0.246, P<0.001) and ventricu-
lar (Pearson R=0.244, P<0.001, Spearman’s Rho=0.221, P<0.001) contractions
increased, while the mean heart rate decreased (Pearson R=-0.448, P<0.001,
Spearman Rho=-0.43, P<0.001).
On the other hand, with increasing in symptoms duration, the number of prema-
ture ventricular contractions increased significantly (Pearson R=0.144, P=0.001,
Spearman’s Rho=0.165, P<0.001) (but not supraventricular) and the mean
heart rate decreased (Pearson R=-0.153, P=0.001, Spearman’s Rho=-0.185,
P<0.001). Multivariate Cox regression analysis showed that the independent pre-
dictors of mortality were age (HR: 1.073, 95% CI 1.055–1.090), the presence
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1.255, 95% CI 1.255–3.462, P<0.001) and the number of premature supraven-
tricular contractions (HR: 1.439, 95% CI 1.168–1.774, P<0.001).
Conclusions: Holter monitoring should be integrated in the periodic evaluation
of FAP V30M-TTR patients. The presence of brady or tachyarrhythmias and the
number of premature supraventricular contractions are associated with unfavor-
able prognosis in these patients and should be treated timely.
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Effects of cognitive behavioral therapy in cardiac electrotherapy
device recipients
M. Sobczak, H. Qawoq, M. Krawczyk, J.D. Kasprzak. Medical University in Lodz,
Dep. of II Chair & Cardiology, Lódz, Poland
Purpose: Modern cardiac electrotherapy (CE) improves health-related quality of
life (QoL), but up to one-third of CE recipients experience psychological distress
after implantation, including anxiety or depression. The purpose of this study was
to evaluate the effects of custom-designed cognitive-behavioral therapy (CBT)
programme in patients undergoing CE.
Methods: Patients qualified for CE device implantation were randomized in or-
der to receive either four weeks of CBT or standard medical care. CBT consisted
of four one-hour sessions conducted over 30 (±3) days with a psychologist (prac-
tice nurse may also perform the therapy), who had received standardized training.
Demographic, clinical and psychological factors were assessed. Beck Depression
Inventory (BDI), State-Trait Anxiety Inventory (STAI), Acceptance of Illness Scale
(AIS), and EuroQol-5D (EQ-5D) health questionnaires were used twice [at base-
line (0), and 6 months after the implantation (6)]. Repeated measures analysis
was used in order to assess the changes in effects of the intervention over time.
Results: We studied 128 patients (36,7% women, mean age 64,5±8,9). There
were no statistically significant differences in psychological parameters be-
tween groups at baseline. The proposed cycle of four structured CBT meet-
ings was well accepted by the patients, which is confirmed by their high
turnout for these meetings. After six months, psychological/QoL indices were
significantly improved in CE recipients assigned to CBT, including: Visual Ana-
logue Scale EQ-5D [80.2±11.8 vs 64.9±14.3 (p<0.0001)], weaker occurrence
of depression symptoms (BDI: 8.4±4.2 vs 11.0±5.2 (p=0.0003), lower anxiety
level [STAI-trait: 31.4±5,9 vs 38.1±9.6 (p<0,0001) and STAI-state: 32.2±5.5 vs
38.5±8.9 (p=0,0001)], and better acceptance of illness [AIS: 35.6±4.3 vs 28.7±6.1
(p<0.0001)]. Interestingly, these benefits were accompanied by better exer-
cise tolerance [6-minute walk test: 392.5±128.2 vs 349.3±106.7 (p=0,02), which
equates 144%±28% vs 129%±18% (p=0,0001)] as compared to the patients sub-
ject to standard care following their electrotherapy.
Conclusions: Our study has important clinical implications for nursing and med-
ical management, caring for the group of patients in question. Custom-designed
protocol of four cognitive-behavioral therapy sessions significantly improved in-
dices of quality of life, depression, anxiety, and acceptance of illness, as well as
exercise tolerance (6MWT) six months after cardiac electrotherapy procedure.
CBT has multiple benefits in this population, as well as ensured the fulfillment of
its expected therapeutical effect, while the short duration of the therapy did not
prolong hospitalization itself.
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Amiodarone- associated altered sterol metabolism - A possible link to
drug-induced steatohepatitis
P. Simonen, J. Lehtonen, H. Gylling, M. Kupari. Heart and Lung Center, Helsinki
University Central Hospital, Helsinki, Finland
Introduction: Amiodarone, a highly effective antiarrhythmic drug is widely used
in suppressing atrial and ventricular tachyarrhythmias. The drug is known to have
many adverse effects including hepatotoxicity, of which the pathogenetic mech-
anism is still evolving. Serum desmosterol level is increased in non-alcoholic
steatohepatitis, and this cholesterol precursor is suggested to have a prominent
role in the pathogenesis of liver inflammation.
Purpose: The present study was conducted to evaluate the effects of long-term
amiodarone treatment on serum non-cholesterol sterols. We assessed the hy-
pothesis that serum desmosterol levels are increased during amiodarone treat-
ment.
Methods: The study population consisted of 56 patients with myocardial inflam-
matory disease (MID) (40 women, 16 men, mean age 53±1.5 (SE) years, body
mass index (BMI) 25±0.9 kg/m2) and 124 healthy controls with similar age, gen-
der and BMI. MID patients were divided into amiodarone (MID drug, n=20) and no
amiodarone (MID control, n=36) treatment groups. Serum lipids were determined
with commercial kits and serum cholesterol precursors (desmosterol and lathos-
terol), plant sterols (campesterol and sitosterol), and cholestanol were measured
with gas-liquid chromatography.
Results: Serum total, LDL, and HDL cholesterol and serum triglyceride con-
centrations were similar between MID drug and MID control groups (eg, total
cholesterol 5.7±0.4 vs 5.6±0.2 (SE) mmol/l, NS), respectively. However, desmos-
terol level was higher in MID drug compared with MID control group (1088±22
vs 83±3 102μmol/mmol of cholesterol, p<0.000001), whereas lathosterol, the
other cholesterol precursor, was similar between the two MID groups (84±6 vs
92±5 102μmol/mmol of cholesterol, NS). In three patients in MID drug group,
desmosterol was analysed before and during amiodarone treatment demonstrat-
ing significantly lower levels prior to treatment (81±4 vs 858±18 102μmol/mmol of
cholesterol, p<0.00001). In MID control group, desmosterol levels did not differ
from those in the healthy controls (78±7 102μmol/mmol of cholesterol, NS). Plant
sterol and cholestanol levels were similar between MID drug and MID control
groups. In spite of increased desmosterol level in MID drug group, serum ala-
nine aminotransferase values were similar to those of MID control group (30±2 vs
26±3 U/l, p=0.09).
Conclusions: The novel observation in the present study was that amiodarone
increased thirteen-fold serum desmosterol level. Desmosterol is known to be toxic
at high levels and may thus have a role in hepatotoxicity associated with amio-
darone treatment.
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Interactions of digitalis and class-III antiarrhythmic drugs: amiodarone
versus dronedarone
G. Frommeyer, C. Ellermann, D. Puckhaber, D. Dechering, C. Pott, L. Eckardt.
Division of Electrophysiology, Department of Cardiovascular Medicine, University
Hospital of Münster, Münster, Germany
Background: A post-hoc analysis of the PALLAS-trial recently suggested pos-
sible interactions of dronedarone and digitalis glycosides. We recently demon-
strated proarrhythmic interactions of this combination in an experimental model.
The aim of the present study was to compare the effects dronedarone or amio-
darone in combination with digitalis glycosides in an experimental whole heart
model.
Methods and results: 11 female rabbits underwent chronic oral treatment with
amiodarone (50mg/kg/d for 6 weeks). 10 rabbits were treated with dronedarone
(50mg/kg/d for 6 weeks). 10 rabbits were used as controls. Hearts were isolated
and Langendorff-perfused. Eight endo- and epicardial monophasic action poten-
tials and a 12-lead ECG showed a moderate prolongation of QT interval and
action potential duration at 90% of repolarization (APD90) as a result of chronic
amiodarone or dronedarone treatment. There was no significant increase in dis-
persion of repolarization. Chronic treatment with dronedarone or amiodarone also
increased effective refractory period (ERP; dronedarone: +22ms, p<0.05; amio-
darone: +23ms, p<0.05).
Additional application of ouabain (0.2μM) resulted in a significant decrease of
QT-interval, APD90, ERP and PRR in all groups. Ventricular arrhythmias were in-
duced by programmed ventricular stimulation and burst stimulation. Reproducible
occurrence was defined as occurrence of at least 3 episodes. Under baseline con-
ditions in control hearts, ventricular fibrillation (VF) was inducible in 1 of 10 hearts
(7 episodes). After application of 0.2μM ouabain 4 of 10 control hearts were in-
ducible (24 episodes). One of 10 dronedarone-pretreated hearts (3 episodes) and
2 of 11 amiodarone-pretreated hearts (6 episodes) showed VF before ouabain in-
fusion. After application of 0.2μM ouabain, 7 of 10 dronedarone-pretreated hearts
were inducible (73 episodes). In contrast, only 4 of 11 amiodarone-pretreated
hearts (13 episodes) showed VF.
Conclusion: In the present study additional treatment with ouabain resulted
in an increased ventricular vulnerability in all study groups. Of note, chron-
ically dronedarone-pretreated hearts were significantly more vulnerable than
amiodarone-pretreated hearts. Ouabain led to a reduction of APD90, ERP, and
post repolarization refractoriness (PRR). This reduction of PRR was more marked
in dronedarone-pretreated hearts that were inducible as compared with all other
groups. These results suggest that combination of amiodarone and digitalis glyco-
sides might not be as harmful as combining dronedarone and digitalis glycosides.
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Long term flecainide therapy in type-3 long QT syndrome
E. Chorin1, R. Taub2, A. Medina2, N. Flint1, S. Viskin1, J. Benhorin1. 1Tel Aviv
Medical Center, Cardiology, Tel Aviv, Israel; 2Shaare Zedek Medical Center,
Cardiology, Jerusalem, Israel
Background: Type 3 long QT syndrome (LQT3) is caused by gain-of-function
mutations in the cardiac sodium channel gene (SCN5A). Previous reports on the
long-term use of sodium channel blockers in LQT3 are sparse.
Objective: To evaluate the long-term safety and efficacy of flecainide therapy in
patients with LQT3 who carry the D1790G SCN5A mutation.
Methods: The study population comprised 30 D1790G carriers who were treated
with flecainide and followed for mean 145+54 months.
Results: The mean baseline (off-drug) QTc was 522+45 ms, and shortened to
469+36 ms with flecainide therapy, a mean decrease of 53 ms [10.1%] (p<0.01).
A QTc longer than 500 ms was evident in 53% of carriers at baseline, and only in
13% on flecainide. All carriers while being compliant with flecainide therapy had
no cardiac events during an average follow up of 83+73 months. Twenty carriers
stopped flecainide after an average follow up of 40+42 months without symptoms.
Six of them (30%) had cardiac events 1–11 months after stopping flecainide. Fle-
cainide induced Brugada-pattern in 6 carriers (20%) was not associated with ar-
rhythmia.
Conclusions: These data suggest that long-term flecainide therapy is relatively
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